Form 4: Theravance Biopharma Executive Reports Stock Transaction
Insider Transaction (Form 4)
Brett A. Grimaud, SVP, GEN COUNSEL AND SECRETARY of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
Summary
- Disposition to the issuer: disposed of 223,917 Ordinary Shares on September 23, 2026; holds 131,251 after (Direct).
- Disposition to the issuer: disposed of 107,812 Ordinary Shares on September 23, 2026; holds 23,439 after (Direct).
- Disposition to the issuer: disposed of 23,439 Ordinary Shares on September 23, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Brett A. Grimaud — Officer (SVP, GEN COUNSEL AND SECRETARY)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 223,917 | — | — | 131,251 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 107,812 | — | — | 23,439 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 23,439 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Disposition to the issuer (223,917 shares) |
| 2026-09-23 | Disposition to the issuer (107,812 shares) |
| 2026-09-23 | Disposition to the issuer (23,439 shares) |
Keywords
insider transaction, Form 4, TBPH, Theravance Biopharma, Inc., neutral, Brett A. Grimaud
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.